Proteomic biomarkers in mid-trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus.
We aimed to explore the proteomic profiles of mid-trimester amniotic fluid in pregnant women with systemic lupus erythematosus (SLE) according to the occurrence of adverse pregnancy outcome (APO). The study population included 35 pregnant women with SLE who underwent clinically indicated amniocentes...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0235838 |
| _version_ | 1818587029981626368 |
|---|---|
| author | Hae Sun Jeon Seung Mi Lee Young Mi Jung Sohee Oh Jin Kyun Park Eun Bong Lee Chan-Wook Park Joong Shin Park Dohyun Han Jong Kwan Jun |
| author_facet | Hae Sun Jeon Seung Mi Lee Young Mi Jung Sohee Oh Jin Kyun Park Eun Bong Lee Chan-Wook Park Joong Shin Park Dohyun Han Jong Kwan Jun |
| author_sort | Hae Sun Jeon |
| collection | DOAJ |
| description | We aimed to explore the proteomic profiles of mid-trimester amniotic fluid in pregnant women with systemic lupus erythematosus (SLE) according to the occurrence of adverse pregnancy outcome (APO). The study population included 35 pregnant women with SLE who underwent clinically indicated amniocentesis at 15-24 weeks of gestation. Patients were divided into two groups according to pregnancy outcomes: SLE patients without APO (Group 1) and SLE patients with APO (Group 2). Stored samples of amniotic fluid were analyzed using mass spectrometry (MS)-based proteomics with two-step approach, consisting of discovery and verification phase. In the discovery phase, 44 proteins were differentially expressed between Group 1 and Group 2. In the verification phase, differentially expressed proteins (DEPs) were verified in independent samples using DIA method. Four proteins including filamin A (FLNA), sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 (SVEP1), lecithin-cholesterol acyltransferase (LCAT), and transglutaminase 2 (TGM2) were differentially expressed both in discovery and verification phase. To select the best combination of proteins for discriminating two groups, three-fold cross validation (CV) with repetition of one hundred times was performed. The multi-marker model with three biomarkers (SVEP1, LCAT, TGM2) had a high discriminatory power to distinguish between the two groups (the area under the receiver operating characteristic, AUROC = 0.946, p <0.001). Our results indicate that the expression of FLNA, SVEP1, LCAT, and TGM2 in mid-trimester amniotic fluid was increased in SLE patients with APO (Group 2). A large-scale prospective study is warranted to verify this finding. |
| first_indexed | 2024-12-16T09:02:22Z |
| format | Article |
| id | doaj.art-445a266c734c40628578674b44224ea4 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T09:02:22Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-445a266c734c40628578674b44224ea42022-12-21T22:37:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01157e023583810.1371/journal.pone.0235838Proteomic biomarkers in mid-trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus.Hae Sun JeonSeung Mi LeeYoung Mi JungSohee OhJin Kyun ParkEun Bong LeeChan-Wook ParkJoong Shin ParkDohyun HanJong Kwan JunWe aimed to explore the proteomic profiles of mid-trimester amniotic fluid in pregnant women with systemic lupus erythematosus (SLE) according to the occurrence of adverse pregnancy outcome (APO). The study population included 35 pregnant women with SLE who underwent clinically indicated amniocentesis at 15-24 weeks of gestation. Patients were divided into two groups according to pregnancy outcomes: SLE patients without APO (Group 1) and SLE patients with APO (Group 2). Stored samples of amniotic fluid were analyzed using mass spectrometry (MS)-based proteomics with two-step approach, consisting of discovery and verification phase. In the discovery phase, 44 proteins were differentially expressed between Group 1 and Group 2. In the verification phase, differentially expressed proteins (DEPs) were verified in independent samples using DIA method. Four proteins including filamin A (FLNA), sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 (SVEP1), lecithin-cholesterol acyltransferase (LCAT), and transglutaminase 2 (TGM2) were differentially expressed both in discovery and verification phase. To select the best combination of proteins for discriminating two groups, three-fold cross validation (CV) with repetition of one hundred times was performed. The multi-marker model with three biomarkers (SVEP1, LCAT, TGM2) had a high discriminatory power to distinguish between the two groups (the area under the receiver operating characteristic, AUROC = 0.946, p <0.001). Our results indicate that the expression of FLNA, SVEP1, LCAT, and TGM2 in mid-trimester amniotic fluid was increased in SLE patients with APO (Group 2). A large-scale prospective study is warranted to verify this finding.https://doi.org/10.1371/journal.pone.0235838 |
| spellingShingle | Hae Sun Jeon Seung Mi Lee Young Mi Jung Sohee Oh Jin Kyun Park Eun Bong Lee Chan-Wook Park Joong Shin Park Dohyun Han Jong Kwan Jun Proteomic biomarkers in mid-trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. PLoS ONE |
| title | Proteomic biomarkers in mid-trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. |
| title_full | Proteomic biomarkers in mid-trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. |
| title_fullStr | Proteomic biomarkers in mid-trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. |
| title_full_unstemmed | Proteomic biomarkers in mid-trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. |
| title_short | Proteomic biomarkers in mid-trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. |
| title_sort | proteomic biomarkers in mid trimester amniotic fluid associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus |
| url | https://doi.org/10.1371/journal.pone.0235838 |
| work_keys_str_mv | AT haesunjeon proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT seungmilee proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT youngmijung proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT soheeoh proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT jinkyunpark proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT eunbonglee proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT chanwookpark proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT joongshinpark proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT dohyunhan proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus AT jongkwanjun proteomicbiomarkersinmidtrimesteramnioticfluidassociatedwithadversepregnancyoutcomesinpatientswithsystemiclupuserythematosus |